CLOs on the Move

Intrexon Corporation

www.dna.com

 
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.dna.com
  • 1872 Pratt Dr, Ste 1400
    Blacksburg, VA USA 24060
  • Phone: 540.961.0725

Executives

Name Title Contact Details

Similar Companies

Repare Therapeutics

Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.

Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

AltPep

AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).

Covx Pharmaceuticals

Covx Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.